

i. Name

DING Jian

ii. Academic qualifications:

1975.11-1978.11 Jiangxi Medical University, Nanchang, China, B.S. in Pathology
1980.9-1983.9 Medical University of China, Shenyang, China, M.A. in Pathology
1986.10-1991.03 Kyushu University, Fukuoka, Jaan, Ph.D. in Pathology

iii. Previous academic positions held:

1991.3-1992.1 Kyushu University Visiting scholar
1992.5-1994.4 Shanghai Institute of Materia Medica, Postdoctoral fellow
1994.4-1995.11 Shanghai Institute of Materia Medica, Principal Investigator/Associate
Researcher
1996.3-2004.11 Shanghai Institute of Materia Medica, Deputy Director/Researcher
2004.12-2013.12 Shanghai Institute of Materia Medica, Director/Researcher
2005.1-2012.1 State key Laboratory of Drug Research, Director, Professor/Researcher
2014.06-2019.05 Shanghai Institute of Materia Medica, Director of Academic Committee

iv. Present academic position:

1995.12-now Shanghai Institute of Materia Medica, Principal Investigator/Researcher
2014.01-now Dean of School of Pharmacy, Chinese Academy of Sciences
2020.08-now Director of the Oncology Center, Shanghai Institute of Materia Medica

v. Present research work:

Anti-tumor drug development, Mechanism study & Biomarker Research & Development

vi. Selected publications records:

Section A (recent five years)

1. Min Huang, Jinjian Lu, **Jian Ding***. Natural Products in Cancer Therapy: Past, Present and Future. *Nat Prod Bioprospect*. 2021; 11(1): 5-13.
2. Yingqiang Liu, Linjiang Tong, Mengge Zhang, Qi Zhang, Qiupei Liu, Fang Feng, Yan Li, Mengzhen Lai, Haotian Tang, Yi Chen, Meiyu Geng, Wenhui Duan*, **Jian Ding***, Hua Xie*. A novel strategy for treating oncogene-mutated tumors by targeting tumor microenvironment and synergistically enhancing anti-PD-1 immunotherapy. *Cancer Commun (Lond)*. 2024; 44(3): 438-442.

3. Mengzhen Lai[#], Tao Zhang[#], Hao Chen, Peiran Song, Linjiang Tong, Jiaying Chen, Yingqiang Liu, Yi Ning, Fang Feng, Yan Li, Haotian Tang, Yi Chen, Yan Fang, Xiaoyun Lu, Meiyu Geng, Ke Ding*, Ker Yu*, **Jian Ding***, Hua Xie*. Discovery of HCD3514 as a potent EGFR inhibitor against C797S mutation in vitro and in vivo. *J Cancer*. 2023;14(1):152-162.
4. Xu Zhang[#], Yuxiang Wang[#], Xi Zhang, Yanyan Shen, Kang Yang, Qingyang Ma, Yuemei Qiao, Jiajie Shi, Yi Wang, Lan Xu, Biyu Yang, Gaoxiang Ge, Landian Hu, Xiangyin Kong, Chunhao Yang, Yi Chen*, **Jian Ding***, Linghua Meng*. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3K α inhibitors. *Signal Transduct Target Ther*. 2023; 8:153.
5. Zonglong Hu, Fan Wei, Yi Su, Yafang Wang, Yanyan Shen, Yanfen Fang, **Jian Ding***, Yi Chen*. Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression. *Signal Transduct Target Ther*. 2023;8(1):11.
6. Yingqiang Liu[#], Zhengsheng Zhan[#], Zhuang Kang[#], Mengyuan Li, Yongcong Lv, Shenglan Li, Linjiang Tong, Fang Feng, Yan Li, Mengge Zhang, Yi Chen, Tao Zhang, Peiran Song, Yi Su, Yanyan Shen, Yiming Sun, Xinying Yang, Yi Chen, Shanyan Yao, Hanyu Yang, Caixia Wang, Meiyu Geng, Wenbin Li*, Wenhua Duan*, Hua Xie*, **Jian Ding***. Preclinical and early clinical studies of a novel compound SYHA1813 that efficiently crosses the blood-brain barrier and exhibits potent activity against GBM. *Acta Pharma Sin B*. 2023;13(12):4748-4764.
7. Hui Xing[#], Mengshi Gao[#], Yuxiang Wang, Xu Zhang, Jiajie Shi, Xiang Wang, Xueling Liu, Qingyang Ma, Xiangyin Kong, Chunhao Yang, **Jian Ding***, Linghua Meng. Genome - wide gain-of-function screening identifies EZH2 mediating resistance to PI3K α inhibitors in oesophageal squamous cell carcinoma. *Clin Transl Med*. 2022 May; 12(5): e835.
8. Pu Sun[#], Xi Zhang[#], RongJing Wang[#], Qing-YangMa, Lan Xu, Yi Wang, Hui-Ping Liao, Hai-Long, Wang, Lan-Dian Hu, Xiangyin Kong*, **Jian Ding***, LingHua Meng*. PI3K α inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8+T cells and promoting fatty acid metabolism. *J Immunother Cancer*. 2021; 9(8): e003093.
9. Qin Xie, Shuaishuai Chi, Yanfen Fang, Yiming Sun, Linghua Meng, **Jian Ding***, Yi Chen*

PI3K α inhibitor impairs AKT phosphorylation and synergizes with novel angiogenesis inhibitor AL3810 in human hepatocellular carcinoma. *Sigal Transduct Target Ther.* 2021;6(1):130.

10. Tao Zhang[#], Rong Qu[#], Shingpan Chan[#], Mengzhen Lai, Linjiang Tong, Fang Feng, Hongyu Chen, Tingting Song, Peiran Song, Gang Bai, Yingqiang Liu, Yanan Wang, Yan Li, Yi Su, Yanyan Shen, Yiming Sun, Yi Chen, Meiyu Geng, Ke Ding*, **Jian Ding***, Hua Xie *.Discovery of a Novel Third-Generation EGFR Inhibitor and Identification of a Potential Combination Strategy to Overcome Resistance. *Mol Cancer.* 2020;19(1):90.

Section B (beyond five years)

1. Xin Wang, Minmin Zhang, Fangfang Ping, Hongchun Liu, Jingya Sun, Yueqin Wang, Aijun Shen*, **Jian Ding***, Meiyu Geng*. Identification and therapeutic intervention of coactivated anaplastic lymphoma kinase, fibroblast growth factor receptor 2, and ephrin type-A receptor 5 kinases in hepatocellular carcinoma. *Hepatology.* 2019; 69:573-586.
2. Xun Huang[#], Juan Yan[#], Min Zhang[#], Yafang Wang[#], Yi Chen, Xuhong Fu, Rongrui Wei, Xingling Zheng, Zhiwei Liu, Xiong Zhang, Hong Yang, Bingbing Hao, Yanyan Shen, Yi Su, Xiaoji Cong, Min Huang, Minjia Tan*, **Jian Ding***, Meiyu Geng*. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-aberrant Solid Tumors. *Cell.* 2018;175(1):186-199.
3. Yafang Wang, Jie Zhang, Yi Su, Yanyan Shen, Dongxian Jiang, Yingyong Hou, Meiyu Geng*, Jian Ding*, Yi Chen*. G9a regulates breast cancer growth by modulating iron homeostasis through the repression of ferroxidase hephaestin. *Nat Commun.* 2017;8(1):274.
4. Xiaoyang Dai*, Juan Yan*, Xuhong Fu, Qiuming Pan, Danni Sun, Yuan Xu, Jiang Wang, Litong Nie, Linjiang Tong, Aijun Shen, Mingyue Zheng, Min Huang, Minjia Tan, Hong Liu, Huang Xun*, **Jian Ding***, Meiyu Geng*. Aspirin inhibits cancer metastasis and angiogenesis via targeting heparanase. *Clin Cancer Res.* 2017;23(20):6267-6278.
5. Qiaoshi Lian[#], Jun Xu[#], Shanshan Yan[#], Min Huang[#]*, Honghua Ding, Xiaoyu Sun, Aiwei Bi, **Jian Ding***, Bing Sun*, Meiyu Geng*. Chemotherapy-induced intestinal inflammatory responses are mediated by exosome secretion of double-strand DNA via AIM2

- inflammasome activation. *Cell Res.* 2017;27(6):784-800.
6. Xihua Yue#, Jing Ai#, Yang Xu #, Yi Chen#, Min Huang, Xinying Yang, Bo Hu, Haotian Zhang, Changxi He, Xinrong Yang, Weiguo Tang, Xia Peng, Liwei Dong, Hongyang Wang, Jia Fan *, **Jian Ding***, Meiyu Geng*. Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. *Hepatology.* 2017;65(6):1948-1962.
 7. Hanlin Zeng #, Jia Qu#, Nan Jin #, Jun Xu, Chenchu Lin, Yi Chen, Xinying Yang, Xiang He, Shuai Tang, Xiaojing Lan, Xiaotong Yang, Ziqi Chen, Min Huang*, **Jian Ding***, Meiyu Geng*. Feedback activation of leukemia inhibitory factor receptor limits response to histone deacetylases inhibitors in breast cancer. *Cancer Cell.* 2016;30(3):459-473.
 8. Aijun Shen#, Lu Wang#, Min Huang, Jingya Sun, Yi Chen, Yanyan Shen, Xinying Yang, Xin Wang, **Jian Ding***, Meiyu Geng*. c-MYC Alterations Confer Therapeutic Response and Acquired Resistance to c-Met Inhibitors in MET-Addicted Cancers. *Cancer Res.* 2015;75(21):4548-59.
 9. Min Huang#, Aijun Shen, **Jian Ding ***, Meiyu Geng*. Molecularly targeted cancer therapy: some lessons from the past decade. *Trends Pharmacol Sci.*2014;35(1):41-50.
 10. Jing Ai#, Qingjuan Tang#, Yanlin Wu #, Yang Xu #, Feng Teng, Ruiyu Zhou, Xin Gao, Qingfeng Zhu, Xihua Yue, Qiuming Pan, Siyun Xu, Jing Li, Min Huangg, Jennifer Daugherty-Holtrop, Yuanzheng He, H. Eric Xu, Jia Fan *, **Jian Ding***, Meiyu Geng*. The Role of Polymeric Immunoglobulin Receptor in Inflammation-Induced Tumor Metastasis of Human Hepatocellular Carcinoma. *J Natl Cancer Inst.* 2011;103(22):1696-712, 2011.

vii. Social Titles

- 1) 2006.12-now, Acta Pharmacologica Sinica, Editor-in-chief;
- 2) 2007.01-now, European Journal of Pharmacology, Editorial board member;
- 3) 2007.01-now, Journal of Ethno pharmacology, Editorial board member;
- 4) 2013.01-2019.1, Molecular Pharmacology, Editorial Advisory Board (EAB) member;
- 5) 2017.04-2022.01, Vice Chairman of Chinese Pharmaceutical Association;
- 6) 2012.07-2021.07, Vice Chairman of the Chinese Pharmacological Society;

7) 2017.04-now, Chairman of Shanghai Pudong New Area Science Association

viii. Awards & Honors

- 1) 2020, the Second National Innovation Competition Award (Medal)
- 2) 2016, Outstanding Scientific and Technological Achievement Award of Chinese Academy of Sciences
- 3) 2016, Tan Jiazhen Life Science Achievement Award
- 4) 2013, National Natural Science Award, 2rd prize
- 5) 2009, National Natural Science Award, 2rd prize
- 6) 2008, Prize of Scientific and Technological Progress of Ho Leung Ho Lee Foundation
- 7) 2006, Wu Jieping Medical-Paul Janssen Pharmaceutical Research Prize
- 8) 2005, Top ten scientific and technological elites (Shanghai)
- 9) 2003, National Science & Technology Award, 2rd prize
- 10) 2001, Fourth International Debio-CCRF Award, 1st Prize